diabetestalk.net

Can You Take Metformin For Type 1 Diabetes?

My Type 1 And Metformin

My Type 1 And Metformin

D.D. Family T1 for 72 years, here to help I was type 1 for about 50 years when I changed from animal insulins to modern day insulins. That led to my gaining weight and becoming insulin resistant (IR). I had to use a type 2 med to handle the IR. Avandia was the med my doctor chose, and I used it successfully for 12 years, starting in 1999. Avandia was found to cause many users to have heart problems, so my endo would not renew my prescription, and he prescribed Metformin in early 2011. I have mixed emotions about Metformin. It has enabled me to lose 22 pounds, and I am now only one pound above my ideal weight (185 pounds). That is great, although I have had to buy new clothes and belts. Lol! My insulin resistance has been decreased, and my insulin sensitivity has increased. That is also good. Metformin was initially introduced as a med to help with weight loss. Later on, it was found to help with with IR. It has caused me to lose some of my appetite, and I don't want to eat as much now. At one time I was losing an average of two pounds per week. To keep from dropping below my ideal weight, I had to increase my carb intake from 130 to 150 carbs per day. My weight has now stabilized. I don't want to eat that many carbs, and sometimes I have to eat when I am not hungry. That is annoying! If I lower my carb intake, then my weight drops too. I have tried lowering my Met dosages, but then my IR increases, and my BG numbers rise a lot. I am taking 1000 mg of Met in the morning and evening. While using Avandia my BG's were very good, and I stayed in the interval 70-130 about 90% of the time. I have used Met for 15 months, and have a lot more highs and lows than before. My BG's are now in the 70-130 range only 66% of the time. BG's as low as the high 30s, and as high as the 170s Continue reading >>

Metformin And Type 1 Diabetes – An Experiment

Metformin And Type 1 Diabetes – An Experiment

Metformin is not usually prescribed for Type 1 diabetes, but over the past couple years, inspired in part by Mike’s experience on it (see here, here, here and here), I’ve become interested in trying it. Not only has it been in widespread use as a treatment for Type 2 diabetes since its approval in 1994, but it’s currently being investigated for potential cognitive and anti-cancer benefits as well. As Mike has asked, “Could metformin be the new aspirin?” The typical explanation for why metformin is not prescribed to people with Type 1 diabetes is that metformin increases your insulin sensitivity — and given that, by definition, people with Type 1 don’t make any insulin, it won’t help them. But I see two obvious holes in that logic. First, people with Type 1 diabetes do have insulin in their bodies; it’s just administered in a different way (i.e. injected subcutaneously, rather than secreted by the pancreas). And as anyone who’s struggled with the dawn phenomenon knows, people with Type 1 diabetes experience insulin resistance, too. And second, metformin does more than just affect insulin sensitivity. It also appears to regulate the genes responsible for causing the liver to release glucose into your blood. As you may know, your pancreas and your liver work closely together to maintain a proper level of glucose in the blood. When you’ve got a lot of glucose in your blood, your pancreas secretes insulin to remove it (provided you don’t have Type 1 diabetes!). And when you don’t have sufficient external glucose – like when you’re sleeping — your liver releases some stored glucose so that your blood sugar does not drop too low. To put this a different way, insulin is what keeps a non-diabetic person’s blood glucose from getting too high; the Continue reading >>

Adjuvant Metformin In Type 1 Diabetes

Adjuvant Metformin In Type 1 Diabetes

Adjunctive metformin may have small short-term benefits, but it provides no added benefit during 10-year follow-up, according to a study published online in Diabetes, Obesity and Metabolism.1 The study is the first retrospective, long-term analysis of metformin as adjuvant therapy to insulin in type 1 diabetes mellitus (T1DM). We conclude that metformin is not associated with long-term beneficial effects on BMI, HbA1c or daily insulin dose when added as adjunct therapy to intensive insulin therapy in T1DM patients, wrote lead author Chantal Mathieu, MD, PhD, of the Laboratory for Clinical and Experimental Endocrinology, KU Leuven, Belgium, and colleagues. Adjuvant metformin is often used off-label in T1DM, owing to its mechanism of action, which may improve glycemic control and decrease insulin dose, weight, and risk of hypoglycemia. While several short-term studies have supported the beneficial effect of adjuvant metformin in T1DM, whether these effects are sustained long term has remained unknown. To evaluate the long-term effects of adjuvant metformin in a real-world setting, researchers used electronic medical records of patients with T1DM seen at University Hospitals Gasthuisberg, Leuven between September 2000 and December 2014. They separated patients into two groups: those who received adjuvant metformin for 6 months or longer (metformin group, n=186) and those who refused metformin or took it for less than 6 months (control group, n=62). They also compared these groups to a baseline reference group of patients with T1DM who were never offered adjuvant metformin (n=961). Hemoglobin A1c (HbA1c), body mass index (BMI), and daily insulin dose were recorded yearly. At baseline, the metformin group had higher BMI and lower insulin doses than the control group. Both g Continue reading >>

Effect Of Metformin In Patients With Type-1 Diabetes With Inadequate Glycaemic Control By Insulin And Diet

Effect Of Metformin In Patients With Type-1 Diabetes With Inadequate Glycaemic Control By Insulin And Diet

Ninety percent of patients with type-1-diabetes will develop late-diabetic complications in the eyes, kidneys, nervous- or cardiovascular-system. Poor glycaemic control is an important risk-factor for development of these late-diabetic complications. The Diabetes Control and Complications Trial (DCCT)-study showed, that improved glycaemic control can prevent the development and progression of these late-diabetic complications. Until now treatment with insulin- and diet-therapy has been the only treatment-modalities available to improve the glycaemic control in patients with type-1-diabetes. A substantial number of these patients still have long-standing poor glycaemic control despite intensive treatment with insulin- and diet-therapy. The antidiabetic drug metformin has shown to be able to improve the glycaemic control in combination with insulin and furthermore reduce both mortality and the risk of developing cardiovascular disease in patients with type-2-diabetes. Only few small studies have investigated the effect of treatment with metformin in patients with type-1-diabetes. These studies have suggested a positive effect of metformin in these patients too. Method: 100 patients with type-1-diabetes with persistent poor glycaemic control i.e. HbA1c > 8.5% during the last 12 months are eligible. Patients are treated for one month with placebo. Hereafter half of the patients will be treated with metformin and the other half continues with placebo for 12 months both as add-on therapy. All patients are continuing ongoing treatment with insulin throughout the study. Before and after the start of treatment with metformin the effect on glycaemic control and other known risk-factors for development of cardiovascular disease i. e. blood-pressure, fasting lipids, urine-albumine- Continue reading >>

Could Taking Metformin Prevent Type 1 Diabetes?

Could Taking Metformin Prevent Type 1 Diabetes?

The Scottish Universities of Exeter and Dundee are combining efforts for a trailblazing new study that aims to find out if lifestyle and environmental factors affect the development of type 1 diabetes and if the most common diabetes drug can be the solution. Metformin is a widely prescribed diabetes drug most often used in the treatment of type 2 diabetes because it increases the body’s sensitivity to insulin, decreases the amount of sugar excreted by the liver, and increases the amount of sugar absorbed by the muscles. Scientists want to find out if metformin can prevent type 1 diabetes by essentially taking some stress off of the body’s hypothetically overworked beta cells. The study is being conducted in Scotland because according to the press release, the country has the 3rd highest incidence of type 1 diabetes in the world, highly organized records of its type 1 diabetes citizens, and a unified group of pediatric diabetologists. JDRF, the charity dedicated to funding type 1 diabetes research is backing the study’s initial costs of $1.7 million. Can Metformin Prevent Type 1 Diabetes in At-Risk Individuals? Researchers plan on contacting every one of the 6,400 families in Scotland with a type 1 diabetes diagnosis and asking children between the ages of 5 and 16 who either have a sibling or a parent with type 1 diabetes diagnosed before the age of 25 to get a blood test. This test will be used to check for antibodies to find out if they are at high risk for developing type 1 diabetes. Those at high risk will be asked to participate in the study called the Accelerator Prevention Trial (adAPT) which will put the children into two groups. One of the groups will take metformin for four months and the other a placebo. The children will be checked three times during t Continue reading >>

Metformin May Not Help Obese Teens With Type 1 Diabetes

Metformin May Not Help Obese Teens With Type 1 Diabetes

home / diabetes center / diabetes a-z list / metformin may not help obese teens with diabetes article Metformin May Not Help Obese Teens With Type 1 Diabetes Want More News? Sign Up for MedicineNet Newsletters! TUESDAY, Dec. 1, 2015 (HealthDay News) -- Metformin is the standby drug for millions of people with type 2 diabetes , but a new study finds that adding it to insulin therapy won't boost blood sugar control for overweight teens with type 1 diabetes . In type 1 diabetes , which comprises about 5 percent of diabetes cases, the body is unable to produce the insulin it needs. So, supplemental insulin is a must for people with the disease. The new study was led by Kellee Miller of the Jaeb Center for Health Research in Tampa, Fla. As her team explained, young people with type 1 diabetes are at even higher metabolic risk if they become overweight or obese , especially in adolescence. That's because both obesity and puberty may cause the patient to require higher levels of supplemental insulin, complicating blood sugar control, the researchers said. Metformin -- a pill taken to help lower blood sugar -- is widely used to treat type 2 diabetes . However, prior studies of how it might affect blood sugar control in teens with type 1 diabetes have been inconclusive, Miller's team noted. The new study involved 140 overweight and obese patients ages 12 to 19 with type 1 diabetes. Each was randomly assigned to take either metformin or a placebo, along with their insulin, for six months. The result: Patients taking metformin showed no improvement in blood sugar (glycemic) control over those taking the placebo. A small beneficial effect from the metformin was seen early on in the study, but it disappeared as the weeks went on. Furthermore, patients who took metformin had more ga Continue reading >>

Metformin In Type 1 Diabetes

Metformin In Type 1 Diabetes

Is this a good or bad idea? The article by Meyer et al. (1) revives a debate regarding the appropriateness of metformin use for people with type 1 diabetes. Given the potential for coexisting lactic acidosis and diabetic ketoacidosis, how can one justify its use? Indeed, there was little reason to expect a benefit in patients who were studied: nonobese type 1 diabetic subjects with HbA1c <9.0% who were taking ∼0.7 units · kg insulin−1 · day−1. A modest average reduction of daily insulin requirements, 4.3 units, as compared with an increase of 1.7 units for placebo, does not seem to be worth the trade-off of increased risk for severe hypoglycemia (19 events in metformin group vs. 8 events in placebo group). There was no differential effect in terms of HbA1c. Only 7 of 31 patients (23%) treated with metformin responded in terms of a significant (20%) reduction in insulin requirement. Furthermore, it is likely that the incidence of hypoglycemia would be much greater if more aggressive metabolic targets of HbA1c had been applied. Despite the failure to observe diabetic ketoacidosis, the limited number and short period of observation does not permit the conclusion that metformin is safe in ketosis-prone diabetic subjects. We have seen a number of type 1 diabetic patients who have received metformin prescriptions by other practitioners. It appears that these prescriptions were given because of a failure to identify latent autoimmune diabetes in adults or because the physician believed that the potential for insulin dose reduction and lipid improvement justified a putative small risk for diabetic ketoacidosis and lactic acidosis. The temptation to prescribe metformin is increased because of the high prevalence of metabolic syndrome among U.S. adults (2). Indeed, the di Continue reading >>

A New Perspective On Metformin Therapy In Type 1 Diabetes

A New Perspective On Metformin Therapy In Type 1 Diabetes

A new perspective on metformin therapy in type 1 diabetes 1 and on behalf of The REMOVAL Study Team 1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA UK 3School of Medicine, University of Glasgow, Glasgow, UK 1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA UK 1Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA UK 3School of Medicine, University of Glasgow, Glasgow, UK John R. Petrie, Email: [email protected] . Received 2017 May 23; Accepted 2017 Jun 27. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. This article has been cited by other articles in PMC. Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk Continue reading >>

Metformin For Type 1 Diabetes - Really? Why?

Metformin For Type 1 Diabetes - Really? Why?

You've heard it before: someone with type 2 diabetes goes on insulin. That's no surprise. But how often have you heard the reverse — someone with type 1 going on Metformin? Since the launch of Symlin in 2005, it's not uncommon for people to treat their type 1 diabetes with a supplemental injectable medication. But hang around long enough, and you too might get to know someone with type 1 who takes insulin and oral meds, those formerly known as "type 2 only" drugs. Really? Type 1's taking oral meds alongside insulin? To clarify this, I just had to query some experts. Just like in type 2 diabetes, people with type 1 diabetes can sometimes suffer from insulin resistance (when the insulin that's present can't perform it's work properly), and Metformin can lower your insulin requirements by helping the body make better use of the stuff — in this case coming from an injection or insulin pump. Gary Scheiner, CDE, author, and head of Integrated Diabetes Services in Wynnewood, PA, explained it this way: "Some of the more creative and aggressive endos are prescribing Metformin for type 1's, particularly if they are overweight or requiring very large basal insulin doses. In addition to having some mild appetite-suppression effects, it will enhance insulin sensitivity by hepatic cells (in the liver) and limit the amount of glucose secreted by the liver. Personally, I think it can be helpful during adolescence as well. As long as the patient has good liver and kidney function, the side effects and risks are negligible." I also learned this: a couple of other uses of Metformin for women to consider are PCOS (ovary disease) and pregnancy. Kelley Champ Crumpler, RN, who is a diabetes nurse educator and a type 1 diabetic married to an endocrinologist with type 1 diabetes (how's that Continue reading >>

Six-month Clinical Trial Reveals Addition Of Metformin Fails To Improve Glycemic Control In Adolescents Living With Type 1 Diabetes

Six-month Clinical Trial Reveals Addition Of Metformin Fails To Improve Glycemic Control In Adolescents Living With Type 1 Diabetes

Six-Month Clinical Trial Reveals Addition of Metformin Fails to Improve Glycemic Control in Adolescents Living with Type 1 Diabetes Showed improvements to cardiovascular risks—reduced weight, BMI, total daily insulin usage BOSTON, December 1, 2015––Six months of adjunctive metformin therapy does not improve glycemic outcomes in obese adolescents with type 1 diabetes, according to new research from T1D Exchange and funded by the JDRF. However, it may have a beneficial effect on measures of obesity, including weight and BMI. The results, published in the current issue of the Journal of the American Medical Association, are from the largest clinical trial to date examining the effect of metformin on overweight and obese adolescents with type 1 diabetes. Though the body mass composition of type 1 patients has traditionally been normal or underweight, recent data from the T1D Exchange shows that adolescents with type 1 diabetes have not escaped the global obesity epidemic. Metformin, an oral medication used primarily to treat type 2 diabetes by helping control blood sugar levels and improving insulin resistance, has shown significant potential benefits among adults. However, studies of adolescents have been small, of short duration, produced inconclusive results or did not focus on overweight and obese adolescents. Thus, the researchers sought to assess the efficacy and safety of metformin as an adjunct therapy in overweight adolescents with type 1 diabetes. They studied changes in HbA1c levels—a fundamental measure of diabetes management—as a primary outcome. They also explored changes in total daily insulin and fluctuations in blinded continuous glucose monitors, BMI/body composition, blood pressure, and lipids. “Being overweight or obese with type 1 diabetes h Continue reading >>

Type 1 Diabetes And Metformin?

Type 1 Diabetes And Metformin?

Diabetes Forum The Global Diabetes Community Find support, ask questions and share your experiences. Join the community I've been a T1D for 16 years now. I've recently had to double my insulin carb ratio within the space of a couple of months (from 1:10 to 1:5) because my control has become really poor. Given my reducing insulin sensitivity, my team suggested metformin. Have any T1s here tried metformin before? Did it help? I honestly don't know whether it'll help solve things! I've been recently in the same boat, with similar ratios, even eating low carb. Decided to try metformin 500g x 2 daily. Been on this for 4 weeks, no issues apart from a minor rash on my back (cannot be certain it is the metformin) which went after 4 days. I believe it takes a few weeks to settle in and the last week I have found I am more sensitive to insulin, so have been reducing my basal, now on 22u from today, was 30u, gradually decreasing every 3 days. My bolus again has reduced, happy with 2-3u per 10g. Don't worry too much about side effects, that's what put me off for years TBH. I just needed to try something to reduce my weight as well and so far, so good. I am T1 and like you my insulin has increased but this has been since having a baby so am assuming I am more insulin resistant and struggle with weight, I have started off on 1 x 500g a day so far had a few loose stools but nothing else really am hoping to see an improvement soon and if I get on ok think they will put me on 2 x 500g. Have any T1s here tried metformin before? Did it help? There are a few type 1 members who take the drug Metformin, here's a thread where Met is being discussed: Yes i have been on Metformin for a few years now and have found it helps with the insulin absorption. Type 1 diagnosed when 11 years old. Howeve Continue reading >>

Metformin In Type 1 Patients Slows Development Of Heart Disease

Metformin In Type 1 Patients Slows Development Of Heart Disease

Scientists believe drug commonly prescribed for T2 could be routinely taken by T1 patients. Metformin is an inexpensive treatment that is often used for type 2 diabetes to lower blood glucose levels by reducing glucose production in the liver. Normally the drug is not regularly given to patients with type 1 diabetes. However, for the first time, a clinical trial has revealed metformin can increase vascular stem cells, which can promote a patient’s ability to repair their own damaged blood vessels. Metformin may be used to lower risk of developing heart disease in patients who have type 2 diabetes, which is the leading cause of illness in type 1 diabetes, accounting for more than half of all fatalities. Dr. Jolanta Weaver, Senior Lecturer in Diabetes Medicine at Newcastle, led two of the studies and believes this new research is a major development in understanding the best ways to further improve treatment in type 1 diabetes. She added that, “As the outcomes of heart disease is worse in diabetic versus nondiabetes patients, there is a need to identify additional treatment options. Metformin could routinely be used by patients with type 1 diabetes to help lower their chances of developing heart disease, by increasing a repair mechanism created by vascular stem cells released from the bone marrow. For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled type 1 diabetes. We have established the drug increases patient’s own vascular stem cells, which will help delay or slowdown heart disease. Our research is an exciting step forward as it may have positive clinical implications for patients with increased risk of cardiovascular disease by improving their treatment Continue reading >>

Is Metformin Effective For Type 1 Diabetes?

Is Metformin Effective For Type 1 Diabetes?

Is Metformin Effective for Type 1 Diabetes? At what point, if any, should one consider the addition of metformin to the regimen of an adherent patient with type 1 diabetes who is not well controlled on insulin? Associate Professor, Department of Pharmacy Practice, Presbyterian College School of Pharmacy; Clinical Pharmacy Specialist, Good Shepherd Free Medical Clinic, Clinton, South Carolina The addition of off-label metformin to insulin therapy to improve insulin sensitivity, promote weight control, and reduce insulin dose requirements in patients with type 1 diabetes has been assessed in systematic reviews.[ 1 , 2 ] One review sought to assess the effects of metformin when added to insulin therapy for type 1 diabetes in adolescents.[ 1 ] The Cochrane Library, MEDLINE, and EMBASE were searched, along with databases of ongoing clinical trials, for randomized controlled trials of at least 3 months' duration. Trials that were included compared metformin added to insulin vs insulin therapy alone. Two trials met inclusion criteria, representing 60 patients in total. Although a lack of heterogeneity made meta-analysis impossible, the authors did note that both studies found a reduction in glycosylated hemoglobin A1c values when metformin was added to insulin. One of the studies also showed a 10% decrease in insulin dosage among those taking metformin. Hypoglycemia and gastrointestinal disturbances were among the most commonly occurring adverse effects of combination therapy. Another systematic review evaluated the addition of metformin to insulin in type 1 diabetes.[ 2 ] This review identified 9 studies, including both adolescents and adults, that involved randomization with informed consent. The studies compared metformin vs placebo or another comparator in parallel or cro Continue reading >>

Metformin Type 1 Diabetes

Metformin Type 1 Diabetes

Inexpensive drug could slow heart disease for Type 1 diabetic patients Scientists at Newcastle University believe a drug commonly prescribed for Type 2 diabetes could be routinely taken by Type 1 diabetic patients to slow the development or delay heart disease. Metformin is an inexpensive treatment that is often used for Type 2 diabetes to lower blood sugar levels by reducing glucose production in the liver. The drug is not regularly given to patients with Type 1 diabetes. However, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells. Our research is an exciting step forward as it may have positive clinical implications for patients with increased risk of cardiovascular disease by improving their treatment options Heart disease is the leading cause of illness in diabetic patients, accounting for more than half of all fatalities. Metformin may be used to lower Type 1 diabetic patients risk of developing this complication. Findings of the clinical trial are published today in the journal, Cardiovascular Diabetology . This follows previous laboratory work at Newcastle University which explored the mechanism behind metformin. Dr Jolanta Weaver , Senior Lecturer in Diabetes Medicine at Newcastle University and Honorary Consultant Diabetologist at Queen Elizabeth Hospital, Gateshead, led both studies. She believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes. Dr Weaver said: As the outcomes of heart disease is worse in diabetic versus non-diabetic patients, there is a need to identify additional treatment options. Metformin could routinely be used by patients with Type 1 diabetes to help Continue reading >>

The Effects Of Metformin In Type 1 Diabetes Mellitus

The Effects Of Metformin In Type 1 Diabetes Mellitus

The effects of metformin in type 1 diabetes mellitus 1Department of Endocrinology and Metabolism, Eskisehir State Hospital, Eskisehir, Turkey 2Department of Medical Biology, Baskent University, Ankara, Turkey 1Department of Endocrinology and Metabolism, Eskisehir State Hospital, Eskisehir, Turkey 2Department of Medical Biology, Baskent University, Ankara, Turkey 3Department of Endocrinology and Metabolism, Ankara Diskapi Teaching and Research Hospital, Ankara, Turkey 4Department of Endocrinology and Metabolism, Kilis State Hospital, Kilis, Turkey 5Department of Endocrinology and Metabolism, Duzce Ataturk State Hospital, Duzce, Turkey Selvihan Beysel, Phone: +90 553 7465802, Email: [email protected] . Received 2017 Mar 16; Accepted 2017 Dec 10. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated. This retrospective study investigated the effect of adding metformin to pharmacologic insulin dosing in type 1 diabetics on insulin therapy 1year after treatment compared with patients on insulin therapy alone. Twenty-nine adults with type 1 diabetes who had metformin added to their insulin therapy for 12months were compared with 29 adults with type 1 diabetes who remained on insulin-alone therapy. Fifty-eight patients with C peptide negative-type 1 diabetics (26 females, mean age: 29.01 7.03years, BMI: 24.18 3.16kg/m2) were analyzed. A Continue reading >>

More in diabetes